Parenteral Low Dose Interferons for Bladder Cancer
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for superficial bladder cancer (SBC) face challenges with high recurrence rates and adverse effects, as existing therapies like intravesical instillation of interferon-alpha have limited efficacy and tolerability due to poor access of the protein to immune cells and systemic side effects from parenteral administration.
Innovation Solution
Parenteral administration of type I interferons at lower doses to achieve sustained exposure and binding to immune cells, activating immune pathways without the high systemic side effects associated with higher doses, potentially combined with chemotherapeutic agents or immunomodulators like BCG.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Object-affected harmful factors
If intravesical instillation of interferon-alpha is used to treat superficial bladder cancer, then the treatment is relatively well tolerated with low grade fever and mild flu-like symptoms, but the efficacy is modest with complete response rates of 40% and responses are rarely durable
Solution Approach 1:
The patent changes the administration route from intravesical to parenteral and adjusts the dose to subtherapeutic levels (below approved doses for other solid tumors), transforming the treatment profile to achieve durable responses with manageable side effects
Solution Approach 2:
The patent uses subtherapeutic doses of interferon-alpha that are below the approved therapeutic doses for other solid tumors, applying a partial action approach where lower doses provide sufficient immune activation without causing excessive systemic toxicity
2Reliability
If parenteral administration of interferon-alpha is used at approved doses for other solid tumors, then systemic exposure is achieved, but severe side effects occur including flu-like symptoms, fever, myalgia, anorexia, nausea, vomiting, myelosuppression, liver toxicity, fatigue, and psychological symptoms
Solution Approach 1:
The patent changes the dose parameter to subtherapeutic levels and the administration route to parenteral, achieving sustained systemic exposure while avoiding the severe side effects associated with high-dose therapy
Solution Approach 2:
The patent applies partial action by using doses below the approved therapeutic threshold for other solid tumors, providing just enough interferon to activate immune cells sustainably without triggering severe systemic toxicity
3Object-affected harmful factors
If intravesical instillation of interferon-alpha is used, then the treatment is well tolerated, but the interferon does not achieve sufficient exposure to immune cells for optimal efficacy
Solution Approach 1:
The patent inverts the administration approach by switching from intravesical to parenteral route, allowing interferon to reach immune cells in the bloodstream and lymphatic system directly rather than attempting local delivery to the bladder
4Reliability
If BCG therapy is used to reduce tumor recurrence, then nearly 75% of patients remain disease free for the first two years, but at least half of all SBC patients receiving BCG will relapse within 5 years and BCG therapy has an unfavorable adverse event profile including cystitis and serious infectious complications
Solution Approach 1:
The patent uses subtherapeutic interferon-alpha as an intermediary agent to modulate the immune system, providing a safer alternative to BCG that achieves durable tumor recurrence reduction without the severe adverse events of live bacterial therapy
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach aims to reduce tumor recurrence and improve tolerability by providing sufficient interferon levels to activate immune cells, potentially offering a more effective and safer treatment option for SBC with reduced side effects compared to traditional methods.
Implementation Method 1
achieve at least half maximal binding of the type I interferon receptor (IFNAR) on immune cells in the bloodstream
Data Source
AI summary
Novel methods and drug products for treating superficial bladder cancer (SBC) are disclosed, which involve parenteral administration of low doses of a type I interferon. The doses used are subtherapeutic for other solid tumors. Use of the novel methods and products in combination with other therapies for SBC is also described.